J&J Discloses New Investigations, Risperdal Agreement

August 15, 2012
Johnson & Johnson (J&J) is facing two new federal investigations into its marketing practices for a drug and a device, just as it is hammering out a settlement over off-label allegations for its antipsychotic Risperdal. J&J subsidiary Janssen Pharmaceuticals is responding to the new Department of Justice request for documents on antibiotic Doribax (doripenem), according to an SEC filing. The company stopped trials on the drug in January after significant safety concerns surfaced.
Washington Drug Letter